Search clinical trials for: PIK3CA-mutant

Total 5 results

Haihe Biopharma Co., Ltd.

Not yet recruiting

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Advanced Breast Cancer
Marina N Sharifi
Novartis; University of Wisconsin, Madison

Recruiting

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | PIK3CA Mutant Metastatic Breast Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Breast Neoplasms

China
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Breast Cancer Stage IV

United States
Genentech, Inc.

Active, not recruiting

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Breast Cancer | Solid Tumor

United States, France, Spain, United Kingdom, Canada

3

Subscribe